ESMO
Search through Resources
No Results Found. Please Try Adjusting Filters
ESMOSunvozertinib Now Available in the US for Previously Treated EGFR Exon 20 Insertion–Mutated NSCLC
ESMOEnozertinib Elicits Responses in Treatment-Naive NSCLC with Atypical EGFR Mutations
ESMOIza-Bren Improves PFS vs Platinum Chemo in EGFR-Mutated NSCLC After Third-Generation TKI
ESMOSavolitinib Combo Extends PFS in Frontline EGFR-Mutated NSCLC and MET Overexpression
ESMOIBI3001 Elicits Responses in EGFR-Mutated NSCLC and Other Advanced Solid Tumors
ESMOSAFFRON Data Reveal New Global SOC in EGFR+ NSCLC With MET Overexpression and/or Amplification After Osimertinib
WCLCAdjuvant Osimertinib in Resected EGFR-Mutated Stage IB-IIIA NSCLC: ADAURA Exploratory 8-Year Overall Survival Landmark Update
WCLCFirmonertinib 160 mg Demonstrates Efficacy in EGFR-Mutated NSCLC With Leptomeningeal Mets
WCLCBH-30643 Shows Activity in EGFR C797S+ NSCLC After Resistance to Prior TKI
WCLCVRN110755 Elicits Responses With Manageable Safety in EGFR C797S+ NSCLC
WCLCAMIGO-1 Trial Meets 18-Month PFS End Point With Frontline Amivantamab Triplet in EGFR+ NSCLC Infographic
WCLCOsimertinib Plus Gefitinib Suppresses Acquired EGFR Resistance Mutations in First-Line NSCLC Infographic
WCLCEarly FLAURA2 Data Show Osimertinib-Chemotherapy Benefit Holds Regardless of Baseline TP53 Status in EGFR+ NSCLC
WCLCEarly Discontinuation of Adjuvant Osimertinib Doubles Recurrence Risk in EGFR-Mutated NSCLC Infographic
WCLCIntercalated Gefitinib Plus Chemotherapy Improves DFS in Resected EGFR-Mutant NSCLC Infographic
WCLCSacituzumab Tirumotecan Elicits Responses in Previously Treated NSCLC With AGAs Other Than Classical EGFR Mutations
WCLCFLAURA2 Data Show Declining AE Frequency Across Osimertinib Treatment Periods in EGFR+ NSCLC
WCLCAMIGO-1 Trial Meets 18-Month PFS End Point With Frontline Amivantamab Triplet in EGFR+ NSCLC
WCLCOsimertinib Plus Gefitinib Suppresses Acquired EGFR Resistance Mutations in First-Line NSCLC
WCLCLiquid Biopsy Shows High Concordance With Tissue Biopsy for EGFR Detection in Stage III NSCLC
WCLCFLAURA2 Data Show Osimertinib-Chemotherapy Benefit Holds Regardless of Baseline TP53 Status in EGFR+ NSCLC
WCLCIntercalated Gefitinib Plus Chemotherapy Improves DFS in Resected EGFR-Mutant NSCLC
WCLCEarly Discontinuation of Adjuvant Osimertinib Doubles Recurrence Risk in EGFR-Mutated NSCLC
ILCCMatthew LeeMillie DasBiomarker Testing and Access Barriers in EGFR-Mutated NSCLC
ILCCMatthew LeeMillie DasMultidisciplinary Toxicity Management in EGFR-Mutated NSCLC
ILCCMatthew LeeMillie DasAdverse Events Prompting Dose Modification in EGFR-Mutated NSCLC
ILCCMatthew LeeMillie DasEmerging Antibody-Drug Conjugate Combinations in EGFR-Mutated NSCLC
ILCCMatthew LeeMillie DasSecond-Line Sequencing After Frontline Progression in EGFR-Mutated NSCLC
ILCCMatthew LeeMillie DasTP53 Co-Mutations and Prognosis in EGFR-Mutated NSCLC
ILCCMatthew LeeMillie DasSelecting Frontline Therapy for High-Risk EGFR-Mutated NSCLC
ILCCTop 5 Highlights from ILCC 2026
ILCCAmy CummingsSandip PatelKey Takeaways and Future Directions in EGFR-Mutated Advanced NSCLC
ILCCAmy CummingsSandip PatelReal-World Experience and Integrating FLAURA2, TOP, and FLAME Into Practice
ILCCAmy CummingsSandip PatelFLAME Data and the Role of ctDNA
ILCCAmy CummingsSandip PatelTP53 Co-Mutation and the TOP Study
ILCCAmy CummingsSandip PatelPoor Prognostic Factors and Frontline Treatment Selection
ILCCEGFR PACC Mutations Define a Distinct NSCLC Subclass With Growing Treatment Options Infographic
ILCCOlivia FankuchenEGFR Channel News Network: On Location at ILCC 2026 with Dr. Olivia Fankuchen
ILCCAmin NassarDeborah DoroshowEGFR Channel News Network: On Location at ILCC 2026 with Dr. Deborah Doroshow and Dr. Amin Nassar
ILCCChristopher GrantEdward B. GaronLyudmila A. BazhenovaNarjust FlorezPasi A. JänneXiuning LeYunpeng YangLung Cancer Experts Debate Disease Nuances to Deliver Patient-Centered Care
ILCCJonathan W. RiessSusan ScottKeeping Future Options Open: Flexibility Across the EGFR Treatment Journey
ILCCJonathan W. RiessSusan ScottShared Decision-Making With Chemotherapy in EGFR+ NSCLC
ILCCJonathan W. RiessSusan ScottThe Importance of Combination Therapy: Understanding Chemotherapy’s Role in Modern EGFR+ Treatment
ILCCJonathan W. RiessSusan ScottUnderstanding the Differences Between Chemotherapeutic Agents: The Misconception Driving Today’s Conversations
ILCCLung Cancer Experts Debate Disease Nuances to Deliver Patient-Centered Care Infographic
ILCCRachel E. SanbornTargeted Therapy Pushes Into Locally Advanced NSCLC as Questions of Duration and Cure Persist
ILCCLyudmila A. BazhenovaTreatment Intensification Benefits Extend Beyond High-Risk EGFR-Mutated NSCLC
ILCCPasi A. JänneSunvozertinib Improves PFS Over Chemotherapy in First-Line EGFR Exon 20–Mutant NSCLC
ILCCXiuning LeEGFR PACC Mutations Define a Distinct NSCLC Subclass With Growing Treatment Options
ILCCEdward B. GaronFrontline Choice Anchors Sequencing Decisions in EGFR-Mutated NSCLC
ILCCFrontline Choice Anchors Sequencing Decisions in EGFR-Mutated NSCLC Infographic
Benjamin P. LevyD. Ross CamidgeGilberto LopesJulia RotowComparing Intensification Strategies and Toxicity Profiles
Benjamin P. LevyD. Ross CamidgeGilberto LopesJulia RotowTP53 Mutations in EGFR-Mutant and Risk Stratification
Ticiana A. LealOptimizing Treatment Selection in Advanced EGFR-Mutated NSCLC: Balancing Efficacy, Toxicity, and Emerging Evidence
D. Ross CamidgeJulia RotowShared Decision-Making and Risk Stratification in EGFR-Mutant NSCLC
ASCOTop 5 Highlights from ASCO 2026
AACRTop 5 Highlights from AACR 2026
Ramaswamy GovindanAdjuvant Erlotinib Does Not Improve OS Over Observation in Resected EGFR-Mutant NSCLC
ASCOJia ZhongFLAME Study Shows Osimertinib Plus Chemotherapy Improves PFS in ctDNA-Persistent EGFR-Mutant NSCLC
ASCOJulia RotowSilevertinib Yields Significant Response Rates in Frontline EGFR Non-Classically–Mutated NSCLC
ASCOESAONA Data Support Asandeutertinib as a Frontline Option in EGFR+ NSCLC With Brain Metastases
ASCODZD6008 Demonstrates Salvage Potential in EGFR C797X–Mutant NSCLC
ASCOSequential Erlotinib Plus Ramucirumab Prior to Osimertinib Fails to Improve Outcomes in EGFR L858R–Mutant NSCLC
ASCOSequential Erlotinib + Ramucirumab Before Osimertinib Does Not Improve Outcomes in EGFR L858R–Mutant NSCLC
ASCOSunvozertinib Shows Superior Efficacy vs Chemo in Frontline Advanced EGFR Exon 20+ NSCLC
ASCORaffaele CalifanoAmivantamab Plus Lazertinib Produces Clinically Meaningful OS in Atypical EGFR-Mutated Advanced NSCLC
ASCOSunvozertinib Outperforms Chemotherapy in Frontline EGFR Exon 20 Insertion–Positive Advanced NSCLC
ASCOAmivantamab + Lazertinib Demonstrates Durable Survival in Atypical EGFR-Mutated Advanced NSCLC
TTLCDeborah DoroshowSandip PatelIntroduction and Frontline Regimen Selection in EGFR-Mutant NSCLC
TTLCDeborah DoroshowSandip PatelManaging Progression in EGFR-Mutant NSCLC: Re-Biopsy, Small Cell Transformation, and CNS Surveillance
TTLCDeborah DoroshowSandip PatelClosing Reflections and Key Takeaways of Optimizing Treatment Selection and Sequencing in Advanced EGFR-Mutated NSCLC: Balancing Efficacy, Toxicity, and Emerging Evidence
TTLCDeborah DoroshowSandip PatelMET-Directed Resistance in EGFR-Mutant NSCLC: Testing, Treatment Matching, and Toxicity Management
TTLCDeborah DoroshowSandip PatelSecond-Line Regimen Choice and Re-Biopsy Realities in EGFR-Mutant NSCLC After Osimertinib
TTLCDeborah DoroshowSandip PatelDatopotamab Deruxtecan and ADC Toxicity Management in EGFR-Mutant NSCLC
TTLCDeborah DoroshowSandip PatelSequencing Strategy in EGFR-Mutant NSCLC: How Frontline Choices Shape Later Options
TTLCDeborah DoroshowSandip PatelPractical Management in EGFR-Mutant NSCLC: Infusion Logistics, Skin Toxicity, and Quality of Life
AACREGFR-Driven Solid Tumors Preclinical Data
AACRHS-10504 Shows Promising Activity in EGFR C797S–Mutant NSCLC After TKI Resistance
Winter LungEGFR-Mutated NSCLC: Acquired Resistance
ELCCTop 5 Highlights From ELCC 2026
Winter LungEGFR-Mutated NSCLC Frontline Treatment
AACRAmivantamab Plus Lazertinib Extends Second-Line PFS in EGFR-Mutant Advanced NSCLC
AACRVRN110755 in EGFR-Mutant NSCLC
ELCCAlissa J. CooperHeather WakeleeJacob SandsEGFR-Mutated NSCLC: Importance of CNS Efficacy in First-Line Treatment
ELCCAlissa J. CooperHeather WakeleeJacob SandsEGFR-Mutated NSCLC: De-escalation of Chemotherapy in Combination Therapy
ELCCHelena A. YuChemotherapy (chemo) Rechallenge in Patients (pts) With Egfr-mutated (EGFRm) Advanced NSCLC Who Discontinued 1L Osimertinib (osi) + Platinum–pemetrexed (plat-pem) Due to Progression (PD): FLAURA2 Exploratory Analysis
ELCCXiuning LeOsimertinib (osi) With or Without Chemotherapy (CTx) as First-line Treatment in EGFR-mutant (EGFRm) Advanced NSCLC With Concurrent TP53 Mutations (TOP Study)
AACRSC3613 Shows Potent Anti-Tumor Activity and Potential for Tolerable Safety in EGFR-Mutant NSCLC Cells
AACRPreclinical Data for EPI-326 Support Clinical Research in EGFR-Responsive Solid Tumors
AACRAmivantamab Plus Lazertinib Extends Second-Line PFS in EGFR-Mutant Advanced NSCLC
AACRVRN110755 Shows Initial Antitumor Activity Across Dose Levels in EGFR-Mutant NSCLC
AACRABK-EGFR-1 Displays Preclinical Activity in EGFR C797S–Driven Xenograft Models
ELCCAlissa J. CooperHeather WakeleeJacob SandsEGFR-Mutated NSCLC: First-Line Treatment Selection in a CNS-Involved Case
ELCCAlissa J. CooperHeather WakeleeJacob SandsEGFR-Mutated NSCLC: Role of Value-Based Frameworks in Treatment Evaluation
ELCCHeather WakeleeHelena A. YuFuture Directions and Unmet Needs in EGFR-Mutant NSCLC
TTLCJonathan W. RiessStructure-Function–Based Classification System Could Refine TKI Selection for Atypical EGFR-Mutant NSCLC Subsets
Jonathan W. RiessNicholas VillanuevaFuture Directions: Toward Personalized EGFR Therapy in NSCLC
Winter LungChristine M. LovlyctDNA and Real-World Data Guide Strategies to Overcome Acquired Resistance in EGFR-Mutated NSCLC
Winter LungEnriqueta FelipJulia RotowSusan ScottUnpacking the Advantages and Limitations of Leading Frontline Regimens in EGFR-Mutated NSCLC
Hawaii LungMET TKIs and ADCs May Broaden Post-Osimertinib Treatment Options in EGFR-Mutant NSCLC
ELCCHeather WakeleeHelena A. YuBuilding a Sequencing Roadmap at Diagnosis in EGFR-Mutant NSCLC
ELCCAlissa J. CooperHeather WakeleeJacob SandsEGFR-Mutated NSCLC: Emerging Role of TROP2-Directed Antibody–Drug Conjugates
ELCCHeather WakeleeHelena A. YuIntegrating ADCs Into the Treatment Paradigm in EGFR-Mutant NSCLC
ELCCAlissa J. CooperHeather WakeleeJacob SandsEGFR-Mutated NSCLC: Integrating Emerging ELCC Data Into Treatment Sequencing
Winter LungBreaking the “Undruggable” Barrier in EGFR Exon 20 Insertion+ NSCLC
Jonathan W. RiessNicholas VillanuevaThe Emerging Role of ADCs in EGFR-Mutant NSCLC
Jonathan W. RiessNicholas VillanuevaSequencing Strategies After Frontline Intensification in EGFR-Mutant NSCLC
Winter LungZosia PiotrowskaEmerging TKIs Drive Renewed Progress in EGFR Exon 20 Insertion–Positive NSCLC
ELCCAlissa J. CooperHeather WakeleeJacob SandsEGFR-Mutated NSCLC: Impact of Subcutaneous Administration on Treatment Experience
ELCCHeather WakeleeHelena A. YuImpact of Co-Mutations on Treatment Strategies in EGFR-Mutant NSCLC
ELCCHeather WakeleeHelena A. YuThe Role of Chemotherapy Rechallenge in EGFR-Mutant NSCLC
ELCCAlissa J. CooperHeather WakeleeJacob SandsEGFR-Mutated NSCLC: Risk–Benefit Assessment in First-Line Treatment Decisions
Jonathan W. RiessNicholas VillanuevaIntegrating ctDNA Into Frontline Decision-Making in EGFR-Mutant NSCLC
Jonathan W. RiessNicholas VillanuevaRethinking High-Risk EGFR-Mutant NSCLC
ELCCDalmelitinib Plus Aumolertinib Shows Durable Activity in MET-Amplified, EGFR-Mutant NSCLC After Progression
Winter LungChristine M. LovlyMatthew LeeNavigating Second-Line Treatment Decisions in EGFR+ NSCLC
ELCCAnalysis Reveals Insights About Chemo Rechallenge After Progression on FLAURA2 Regimen in EGFR+ Advanced NSCLC
ELCCHeather WakeleeHelena A. YuInterpreting FLAURA2 for Sequencing Strategies in EGFR-Mutant NSCLC
ELCCHeather WakeleeHelena A. YuFrontline Decision-Making in EGFR-Mutant NSCLC
ELCCAlissa J. CooperHeather WakeleeJacob SandsEGFR-Mutated NSCLC: Interpreting Efficacy Outcomes in First-Line Therapy
ELCCAlissa J. CooperHeather WakeleeJacob SandsEGFR-Mutated NSCLC: Evolving First-Line Treatment Landscape
Jonathan W. RiessNicholas VillanuevaInterpreting Overall Survival Data With Combination Strategies in EGFR-Mutant NSCLC
Laura AlderSamuel RosnerThe Future of EGFR+ NSCLC Management
Jonathan W. RiessNicholas VillanuevaThe Evolution of Frontline Therapy in EGFR-Mutant NSCLC
ELCCDato-DXd Confers Clinical Benefit Regardless of TROP2 NMR Status in EGFR-Mutant NSCLC
ELCCBreakthrough in Pretreated EGFR-Mutated NSCLC
ELCCSac-TMT Extends OS in Pretreated EGFR-Mutated NSCLC
ELCCAdding LCT to Osimertinib Improves PFS Outcomes, Local Control Rates in EGFR-Mutated NSCLC
ELCCOsimertinib Plus Chemotherapy Doubles PFS in EGFR-, TP53-Mutant Advanced NSCLC
ELCCAdding Local Consolidative Therapy (LCT) to Osimertinib Significantly Improves PFS in EGFR-Mutated NSCLC
ELCCOsimertinib + Chemotherapy Doubles Progression-Free Survival in High-Risk NSCLC
Winter LungChristine M. LovlyMatthew LeeHow Risk Benefit Profiles Aid in Treatment Selection in EGFR+ NSCLC
Laura AlderSamuel RosnerPromoting Treatment Adherence and Managing AEs in EGFR+ NSCLC
Laura AlderSamuel RosnerWhere ADCs Fit in the EGFR+ NSCLC Treatment Paradigm
Laura AlderSamuel RosnerSequencing Considerations After the MARIPOSA or FLAURA-2 Regimens in EGFR+ NSCLC
Laura AlderSamuel RosnerSequencing in EGFR+ NSCLC: How MET Amplifications and Other Factors Guide Decisions
TTLCNatalie I. U. VokesSid DevarakondaOngoing Research to Watch in EGFR-Mutated NSCLC
TTLCNatalie I. U. VokesSid DevarakondaExperiences With ADCs in EGFR-Mutated NSCLC Management
TTLCNatalie I. U. VokesSid DevarakondaRemaining Evidence Gaps in EGFR-Mutated NSCLC Care
TTLCNatalie I. U. VokesSid DevarakondaResistance Mechanisms in EGFR-Mutated NSCLC
TTLCNatalie I. U. VokesSid DevarakondaEvolving Frontline Treatment Options in EGFR-Mutated NSCLC
TTLCNatalie I. U. VokesSid DevarakondaSequencing Considerations in Advanced EGFR-Mutated NSCLC
TTLCNatalie I. U. VokesSid DevarakondaRisk Factors That Help Inform Treatment Selection in Frontline EGFR-Mutated NSCLC
Laura AlderSamuel RosnerDetermining When to Utilize Combination Approaches in EGFR+ NSCLC
Laura AlderSamuel RosnerFactors Driving Treatment Decision-Making in Frontline EGFR+ NSCLC
Hawaii LungJoel NealSarah GoldbergToxicity Considerations With ADCs and Other Approaches in EGFR-Mutated NSCLC
Hawaii LungJoel NealSarah GoldbergHow Frontline Therapy Affects Sequencing Considerations in EGFR-Mutated NSCLC
Hawaii LungJoel NealSarah GoldbergAE Management With Subcutaneous Amivantamab in EGFR-Mutated NSCLC
Hawaii LungJoel NealSarah GoldbergThe Role of Amivantamab Plus Lazertinib in EGFR-Mutated NSCLC Management
Hawaii LungJoel NealSarah GoldbergNavigating Treatment Decisions for EGFR-Mutated NSCLC With High-Risk Features
Hawaii LungJoel NealSarah GoldbergFactors Driving Frontline Treatment Selection in EGFR-Mutated NSCLC
Time Toxicity and Treatment Selection in EGFR-Mutated NSCLC
The Role of Tumor Burden on Treatment Selection in EGFR-Mutated NSCLC
Utilizing NCCN Guidelines for Treatment Guidance in EGFR-Mutated NSCLC
How Subcutaneous Amivantamab Fits into EGFR-Mutated NSCLC Management
Data from PALOMA-3 for Subcutaneous Amivantamab in EGFR-Mutated NSCLC
Factors Informing First-Line Treatment Selection in EGFR-Mutated NSCLC
WCLCUpdated OS Data Reshape First- and Second-Line Treatment Selection in EGFR-Mutated Advanced NSCLC
FDA Approves Subcutaneous Amivantamab for EGFR+ NSCLC
ESMOJulia RotowNarjust FlorezEGFR-Mutated NSCLC: Using Post-Progression Data to Guide 1L Strategies
ESMOJulia RotowNarjust FlorezEGFR-Mutated NSCLC: Balancing Efficacy, Toxicity, and Patient Factors
ESMOJulia RotowNarjust FlorezEGFR-Mutated NSCLC: Refining Patient Selection for Monotherapy vs Combination Therapy
CFSBenjamin P. LevyJonathan W. LeeAdvances in EGFR-Mutant, HER2-Positive, and Oncogene-Driven NSCLC Highlighted at CFS: With Benjamin P. Levy, MD, and Jonathan W. Lee, MD, MSc
NCCN Releases NSCLC Guideline Update, Dato-DXd Designated as a Preferred Second-Line Regimen in EGFR-Mutated Disease
ESMOOsimertinib Plus Chemo Outperforms Single-Agent Osimertinib Regardless of Prognostic Factors in EGFR+ NSCLC
WCLCPasi A. JänneFLAURA2: Exploratory Overall Survival (OS) Analysis in Patients (Pts) with Poorer Prognostic Factors Treated with Osimertinib (Osi) ± Platinum-Pemetrexed Chemotherapy (CTx) as First-Line (1L) Treatment (Tx) for EGFR-Mutated (EGFRm) Advanced NSCLC
WCLCEdward B. GaronHelena A. YuTiciana A. LealZosia PiotrowskaMARIPOSA-2 Toxicity Management: Amivantamab Delay vs Dose Reduction
WCLCEdward B. GaronHelena A. YuTiciana A. LealZosia PiotrowskaContinuing Osimertinib in the 2L Treatment Setting: Data From COMPEL
ESMOPasi A. JänneDr. Jänne on OS Benefit With Osimertinib Plus Chemo by Poor Prognostic Factors in EGFR+ NSCLC
WCLCEdward B. GaronHelena A. YuTiciana A. LealZosia PiotrowskaPemetrexed Maintenance Duration and Toxicity Management
Antonio PassaroDr. Passaro on the Role of MET in Guiding Treatment Strategies After EGFR TKI Progression in NSCLC
WCLCEdward B. GaronHelena A. YuTiciana A. LealZosia PiotrowskaThe Impact of SKIPirr and COCOON Protocols on Amivantamab Toxicities
WCLCEdward B. GaronHelena A. YuZosia PiotrowskaDifferentiating Between the Risk-Benefit Profiles for the Combination Therapies
WCLCEdward B. GaronHelena A. YuTiciana A. LealZosia PiotrowskaIdentifying High-risk Patient Populations Benefitting From Combination Therapy in the Frontline
WCLCJacob SandsIntracranial Efficacy of Datopotamab Deruxtecan (DatoDXd) in Patients With Advanced/Metastatic NSCLC in TROPION-Lung01
WCLCSandip PatelFirst-Line Osimertinib Chemo vs Osimertinib Mono in EGFRm Advanced NSCLC: Flaura2 Final Overall Survival
ASCOElvire Pons-TostivintDato-DXd Leads to Intracranial Responses in Advanced/Metastatic NSCLC With Brain Metastases
WCLCGiulia PaselloContinuing Osimertinib Plus Chemo After Progression Improves PFS in EGFR-Mutated NSCLC
Gilberto LopesDr. Lopes on a Cost Analysis of Osimertinib/Chemo vs Amivantamab/Lazertinib in EGFR+ NSCLC
ILCCUnderstanding Underlying Resistance Mechanisms is Vital for Guiding Treatment Selection Post-Osimertinib in EGFR+ NSCLC
Balazs HalmosDr. Halmos on the FDA Approval of Dato-DXd for Advanced/Metastatic EGFR-Mutated NSCLC
ASCONeoadjuvant Osimertinib Yields MPRs With or Without Chemotherapy in Resectable EGFR-Mutated NSCLC
ASCOCOCOON DM Regimen Reduces Amivantamab/Lazertinib Effects on QOL in EGFR-Mutated NSCLC
ASCOAmivantamab Plus Chemo Maintains PFS Benefit in EGFR+ NSCLC Regardless of Osimertinib Resistance Mechanism
ASCORaffaele CalifanoDr. Califano on MARIPOSA-2 Outcomes by Baseline Resistance Mechanisms in EGFR+ NSCLC
Helena A. Yu56-Year-Old Never-Smoker Female with High-Risk Metastatic EGFR-Mutant NSCLC Treated with the FLAURA2 Regimen
Suresh S. RamalingamOsimertinib After Definitive Chemoradiotherapy in Patients with Unresectable Stage III EGFRm NSCLC: Updated Overall Survival Analysis From the LAURA Study
ESMOHatim HusainJonathan W. RiessJoshua E. ReussJulia RotowManaging Toxicities With TROP2-Directed ADCs in Advanced NSCLC: Best Practices and Management Strategies
ASCOCharu AggarwalIntracranial Efficacy of Datopotamab Deruxtecan in Patients With Previously Treated Advanced/Metastatic Non-Small Cell Lung Cancer With Actionable Genomic Alterations: Results From TROPION-Lung05
ASCODato-DXd Demonstrates Intracranial Activity in Advanced NSCLC With/Without Brain Metastases
